Clear cell renal carcinoma metastasis mimicking primary thyroid tumor

Krzysztof Kaliszewski¹, Danuta Szkudlarek², Michał Kasperczak³, Łukasz Nowak¹

¹ 1st Department and Clinic of General, Gastroenterological and Endocrine Surgery, Wrocław Medical University, Wrocław, Poland
² Department of Pathomorphology, Wrocław Medical University, Wrocław, Poland
³ Department of Physiotherapy, Wrocław Medical University, Wrocław, Poland

Introduction  Secondary tumors of the thyroid gland occur very rarely and constitute an uncommon cause of thyroid enlargement. Usually, they manifest as widespread malignant processes or as a thyroid invasion from other malignancies or affected adjacent organs or tissues.

Metastases of clear cell renal carcinoma (CCRC) to the thyroid gland are also rare, although CCRC is the most common malignant tumor that metastasizes to this organ. It might be connected with epidemiology, which shows that the occurrence of CCRC has been rising steadily, increasing by 2% to 4% per year. If thyroid metastases of the CCRC coexist with multinodular goiter, potential diagnostic difficulties may appear. However, in some cases, even a solitary metastatic mass localized unilaterally in the thyroid gland may imitate a primary thyroid lesion. An extremely rare manifestation of thyroid CCRC metastasis might be the active bleeding of the thyroid gland. Regardless of the high sensitivity and specificity of some diagnostic modalities to detect thyroid nodules, many of them are still insufficient for the diagnosis of thyroid metastatic tumors. The situation might be even more challenging when the thyroid nodule is the initial manifestation of renal disease. Diagnostic and therapeutic difficulties are common in the management of thyroid tumors.

We undertook this study to emphasize that it is important to include a CCRC metastasis to the thyroid gland in a differential diagnosis before referring a patient for surgery. We sought to assess the occurrence of this secondary tumor in comparison with all benign and malignant thyroid lesions, efficacy of diagnostic methods and surgical treatment, and patient survival.

Patients and methods  We retrospectively analyzed the medical records of consecutive patients who underwent surgical treatment due to thyroid pathology in a single center between 2008 and 2016. Among the 4327 patients with thyroid tumors, 384 (8.87%) had thyroid malignancy and 10 (0.23%) were diagnosed with secondary tumor. Finally, 9 patients (0.2%) with a CCRC metastasis mimicking a primary thyroid tumor were identified. We analyzed and compared the clinical and pathological characteristics of patients with metastatic CCRC of the thyroid gland. The collected data included demographic characteristics of patients, clinical manifestations, imaging studies, tumor characteristics, treatment modalities, and final outcome. All data were obtained from the medical records and interviews with patients or their relatives. All patients underwent an ultrasound-guided fine-needle aspiration biopsy (FNAB) before surgery. All cytologic and histopathologic specimens were reanalyzed, and final diagnoses were graded according to the 8th TNM staging classification for urologic cancers.

The study was approved by the ethics review board (No. KB-296/2015).

Results  Metastatic CCRC occurred in 6 women and 3 men (mean age, 68 years [range, 43–81 years]). Almost all patients (7 of 9) underwent unilateral nephrectomy due to CCRC a minimum of 5 years before thyroid tumor appearance (mean, 9.7 years [range, 5–13 years]). In 2 of the 9 patients, the thyroid mass was the initial manifestation of CCRC. Symptoms of thyroid tumor were present for a mean of 6 months. In 2 of the 9 patients, an unspecified malignancy was suspected on the basis of ultrasound-guided FNAB (category V according to the Bethesda System for Reporting Thyroid Cytopathology). In 7 cases, metastases of CCRC affected the right lobe of the thyroid as a solitary mass (mean diameter, 38 mm [range, 26–60 mm]). In 2 individuals, metastases were localized in the left lobe. Total thyroidectomy was performed in 7 patients; nonradical surgery, in 1 patient; and tracheostomy, in 1 patient. Five patients died due to dissemination of the disease.
TABLE 1

| No. | Sex | Age at CCRC diagnosis, y | Treatment modality | Further management | Status | Disease-free survival, mo | OS since CCRC diagnosis, mo | Immunohistochemistry |
|-----|-----|-------------------------|-------------------|-------------------|--------|--------------------------|-----------------------------|----------------------|
| 1   | F   | 69                      | Total thyroidectomy | PET scans revealed the presence of micronodules in the lungs. | Deceased | 50                       | 144                         | Vimentin, CD10, CK7, CK19, HBME-1, CgA |
| 2   | M   | 81                      | Total thyroidectomy | Imaging studies (CT, ultrasound) excluded new disease. | Deceased not due to CCRC metastasis | 26                       | 179                         | CK8/18, CD10, RCCM |
| 3   | F   | 72                      | Hemithyroidectomy  | Patient refused further diagnostic workup. | Deceased | 36                       | 141                         | Vimentin, EMA, CD10, RCCM, CK7, S-100 |
| 4   | F   | 61                      | Total thyroidectomy | PET/CT scans revealed the presence of a renal nodule; patients underwent right nephrectomy. Histopathology confirmed CCRC. | Alive, no evidence of disease | 71                       | 72                          | Tg, TTF, vimentin, EMA, Syn, CgA, CD10, RCCM |
| 5   | F   | 77                      | Total thyroidectomy | PET/CT revealed lung and brain metastasis. | Deceased | 12                       | 137                         | CK8/18, CD10, RCCM |
| 6   | F   | 67                      | Total thyroidectomy | Without new signs on imaging studies, systematic follow-up | Alive, no evidence of disease | 48                       | 156                         | Vimentin, EMA, CD10, RCCM, CK7, S-100 |
| 7   | M   | 43                      | Tracheostomy/ surgical biopsy | – | Deceased | 0                         | 0                          | Vimentin, CD10, CK7, CK1/3, CK19, p63, desmin, calcitonin, CgA, RCCM |
| 8   | F   | 78                      | Total thyroidectomy | PET scans revealed lung metastasis. | Deceased | 6                        | 145                         | CK8/18, vimentin, CD10, CK19, HBME-1, cyclin D1, S-100, CD34 |
| 9   | F   | 64                      | Total thyroidectomy | Without new signs on imaging studies, systematic follow-up | Alive, no evidence of disease | 24                       | 168                         | CK8/18, CD10, RCCM |

Abbreviations: CCRC, clear cell renal carcinoma; CT, computed tomography; EMA, epithelial membrane antigen; F, female; HBME-1, Hector Battifora mesothelial-1; M, male; OS, overall survival; PET, positron emission tomography; RCCM, renal cell carcinoma marker; TTF, thyroid transcription factor

Discussion  Clear cell renal carcinoma accounts for 3% of all malignant tumors in the general population and is the third most frequent urologic cancer. It is also the most common subtype of renal malignancy and accounts for approximately 70% to 80% of all cases. Moreover, CCRC is associated with approximately 13,000 deaths per year. Metastases in patients with CCRC are not very rare. The prevalence of solitary CCRC metastases is approximately 4%. The most common metastatic sites are the lungs, adrenal glands, gastrointestinal tract, brain, lymph nodes, bone,
and liver, while the thyroid gland is the most common site of CCRC metastasis within the head and neck region. Approximately 25% to 48.1% of all secondary thyroid tumors are attributed to CCRC. Nevertheless, the thyroid gland is considered an atypical localization of CCRC metastases, along the orbits, parathyroid glands, nasal and paranasal cavities, tongue, tonsils, heart, skin, muscles, and joints.

The majority of patients present a metastatic thyroid tumor many years after an initial CCRC diagnosis and effective treatment. There have been several reports of late metastasis from CCRC, which may occur even many years after nephrectomy. Prolonged disease-free intervals might be observed, with an average period of 7.5 years.

Heffess et al emphasized the high vascularity of the thyroid gland and stressed the fact that metastases to this gland are rarely observed in clinical practice. Usually, the thyroid is the most common metastatic site for lung, kidney, breast, skin, and stomach cancers. However, even malignant melanoma metastasis to the thyroid might be isolated. There are some hypotheses explaining why CCRC metastasis to the thyroid gland is rare. According to the most recent theory, high oxygen and low carbohydrate thyroid tissue concentrations, large amounts of iodine, and high vascularity are the reasons for low incidence. All of these factors protect thyroid vessels from malignant cell embolization. Thus, it may be concluded that pathological changes in thyroid tissue are a risk factor for the proliferation of metastatic cells. It might be the reason why we observed metastatic tumors in the multinodular goiter of 4 patients. A thyroid tumor might also be isolated.

Asth et al emphasized that in such a situation, the thyroid metastasis of CCRC may be mimicking a primary thyroid tumor. A thorough diagnostic work-up with biochemical tests, imaging studies, and ultrasound-guided FNAB is recommended in these patients.

Clear cell renal carcinoma is curable with surgery; however, metastasis from the kidney may develop in many organs, such as the lungs, liver, bone, and thyroid. Thyroidectomy due to metastasis is a common treatment option for oligometastatic disease and is often considered in patients who develop a metastasis after renal resection or as an alternative treatment when systemic therapy fails.

In our study, 7 patients underwent radical thyroidectomy due to CCRC metastasis. In 1 patient, we resected a single lobe of the thyroid gland, and in another patient, only a tracheostomy was performed owing to an advanced malignant process. Of the 7 patients who underwent radical surgery, 3 are still alive. The prognosis for metastatic CCRC is rather poor, with a median survival of only approximately 2 years and a 5-year survival rate of less than 10%. There are several factors associated with favorable prognosis when radical surgery is performed: a long interval between the occurrence of CCRC and manifestation of thyroid metastases, a solitary metastatic tumor, absence of disease dissemination, the presence of necrotic tissue in metastatic tumors, and a slow development of the metastases. In our study, the longest interval between CCRC development and metastasis manifestation was 13 years. Thyroid metastases of CCRC presented as a solitary tumor in 5 patients. Dissemination of the disease was observed in 3 patients, and 1 patient refused further diagnostic workup. We did not observe necrotic tissue in metastatic tumors in any of the patients.

Histopathologic features that may indicate the metastatic nature of a thyroid tumor include the histologic similarity to the primary tumor, different architecture than in primary thyroid tumors, the presence of small deposits within the lymphatic spaces, or a solitary mass. A cyologic evaluation revealed the characteristic features of CCRC, such as clear cytoplasm, distinct cell membranes, and small nuclei. Moreover, in histologic examinations, a rich network of blood vessels, as well as spaces filled with extravascular erythrocytes, could be observed. The histopathologic examination of the presented cases showed a clear cell carcinoma immunoreactivity for vimentin and CD10, occasional immunoreactivity for renal cell carcinoma marker (RCCM), and negative immunoreactivity for cytokeratin 19, Hector Battifora mesothelial-1, and chromogranin, confirming the renal origin of the tumor.

The characteristic immunohistochemical profile for CCRC is positive for vimentin, cytokeratin antibodies AE1/AE3, CD10, RCCM, PAX2 and PAX8 proteins, and CAIX enzyme, and negative for high-molecular-weight cytokeratin, CK7, CK20, CD117, kidney-specific cadherin, and parvalbumin.

In all patients with multinodular goiter or with a single mass localized in the thyroid gland and previously treated due to CCRC, metastasis to the thyroid gland should be considered in a differential diagnosis. However, a thyroid tumor might also be a primary manifestation of CCRC. Ultrasound-guided FNAB is still an insufficient diagnostic method in secondary thyroid tumors. Radical surgery is the main therapeutic option for CCRC metastasis to the thyroid gland; nevertheless, in some cases, only a palliative procedure may be performed.

**ARTICLE INFORMATION**

**CONFLICT OF INTEREST** None declared.

**OPEN ACCESS** This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercialShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.

**HOW TO CITe** Kaliszewski K, Sekulbier K, Kasprowska M, Novak L. Clear cell renal carcinoma metastasis mimicking primary thyroid tumor. Pol Arch Intern Med. 2019; 129: 211-214. doi:10.20452/pamw.4425.
REFERENCES

1. Jackson G, Fino N, Bitting RL. Clinical characteristics of patients with renal cell carcinoma and metastasis to the thyroid gland. Clin Med Insights Oncol. 2017; 11: 117954917743981.
2. King SC, Pollack LA, Li J, et al. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol. 2014; 191: 1665-1670.
3. Abbassi Z, Strano F, Koliakos E, et al. Thyroid bland hemorrhage in a patient with past medical history of renal clear cell carcinoma: report of a very rare case. Am J Case Rep. 2018; 19: 920-923.
4. Czopnik P, Aporowicz M, Niepokój-Czopnik A, et al. Primary thyroid lymphoma: a rare but challenging diagnosis. Pol Arch Intern Med. 2017; 127: 361-364.
5. Ohba K, Miyata Y, Mitsunari K, et al. Left atrial metastasis of renal cell carcinoma: A case report and review of the literature. BMC Res Notes. 2014; 7: 520.
6. Koul H, Huh JS, Rive KO, et al. Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res. 2011; 1: 240-254.
7. Valdair F. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015; 48: 166-174.
8. Shi JL, Zhou JQ, Li JP. Renal clear cell carcinoma with thyroid and parotid metastases: a case report. Oncol Lett. 2015; 10: 2617-2619.
9. Sountoulides P, Metaxa L, Cindolo L. Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports. J Med Case Rep. 2011; 5: 429.
10. Heffess CS, Wenig BM, Thompson LD. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. Cancer. 2002; 95: 1869-1878.
11. Szczepanek-Panulska E, Piątek K, Majewski P, et al. Unsuspected melanoma misdiagnosed as anaplastic thyroid carcinoma in fine-needle aspiration biopsy. Pol Arch Med Wewn. 2013; 123: 558-559.
12. Astl J, Bahannan AA, Duskova J, et al. Solitary metastasis of clear renal cell carcinoma to thyroid gland: Three reported cases with review of the literature. Gulf J Oncolog. 2017; 1: 67-71.